In the systematic review's pharmacovigilance analysis, semaglutide had an inverse reporting odds ratio of 0.238; the specific reported event and comparator were not stated.
In plain wordsIn reviewed multiple-sclerosis pharmacovigilance data, semaglutide had inverse reporting odds; the event and comparator were unstated.
- Peptide
- Semaglutide
- Outcome
- DecreasePharmacovigilance reporting odds ratio
- Study
n: not reported in source
- Outcome group
- Adverse events · Pharmacology
- Studied dose
- Dose not stated
Measurements
- reporting odds ratio
- 0.238
- semaglutide
Source sentences
Pharmacovigilance showed inverse reporting odds ratios with semaglutide (ROR 0.238), dulaglutide (ROR 0.165), and liraglutide (ROR 0.161).
5 context sentences(design, population, supporting numbers)
We conducted a PROSPERO-registered systematic review (CRD420261385854) following PRISMA 2020 guidelines.
PubMed/MEDLINE and Scopus were systematically searched to June 12, 2026.
Studies examining GLP-1RAs in confirmed MS patients, EAE animal models, or case reports were eligible.
Narrative synthesis followed SWiM guidelines.
Fifteen studies met inclusion criteria: eight preclinical animal studies (six EAE, two cuprizone models), four human observational studies, and three narrative-context studies.